Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

ASCO 2026: Updates in testicular, germ cell and rare genitourinary cancer

ASCO 2026

29 May - 2 Jun 2026

Published: 22 Jun 2026

Views: 28

Rating:

Save

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina

Dr Natalia Gandur speaks to ecancer about updates in testicular, germ cell and rare genitourinary cancers from ASCO 2026.

She explains that in testicular cancer the main updates centre around better surveillance, better relapse detection and better survivorship.

Dr Gandur also covers salvage therapy, teratoma, high-dose chemotherapy and poor-risk germ cell tumour care.

Related Videos

ASCO 2026: Updates in bladder cancer

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina

ASCO 2026: Updates in bladder cancer ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )

Understanding patient expectations and clinicians' goals in favourable risk aRCC patients

Prof Daniele Santini and Dr Yann Alexandre Vano

Understanding patient expectations and clinicians' goals in favourable risk aRCC patients ( Prof Daniele Santini and Dr Yann Alexandre Vano )

miR371 shows promise as a surveillance biomarker for relapse in early-stage germ cell tumours

Dr Lucia Nappi - University of British Columbia, Vancouver, Canada

miR371 shows promise as a surveillance biomarker for relapse in early-stage germ cell tumours ( Dr Lucia Nappi - University of British Columbia, Vancouver, Canada )

ASCO 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke

ASCO 2026: Latest updates in mRCC ( Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke )

Tepotinib in second line NSCLC treatment

Dr Antonio Passaro and Prof Raffaele Califano

Tepotinib in second line NSCLC treatment ( Dr Antonio Passaro and Prof Raffaele Califano )

MRD validated as a surrogate endpoint for survival in AML

Dr Jesse Tettero - The Hourigan Lab, Washington, D.C., USA

MRD validated as a surrogate endpoint for survival in AML ( Dr Jesse Tettero - The Hourigan Lab, Washington, D.C., USA )

New MOAs in prostate cancer treatment - what’s next?

Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini

New MOAs in prostate cancer treatment - what’s next? ( Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini )

Insights into germline genetic screening of breast cancer patients

Dr Teresa Ramón y Cajal, Dr Marjanka Schmidt and Dr Seigo Nakamura

Insights into germline genetic screening of breast cancer patients ( Dr Teresa Ramón y Cajal, Dr Marjanka Schmidt and Dr Seigo Nakamura )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

More from ecancer